Renerve (ASX:RNV) ROCE %: -113.87% (As of Dec. 2025)


What is Renerve ROCE %?

Renerve ASX:RNV +1.27% ROCE % is -113.87% as of Dec. 2025. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Renerve's annualized ROCE % for the quarter that ended in Dec. 2025 was -113.87%.

Renerve  (ASX:RNV) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Renerve ROCE % Related Terms

Renerve ROCE % Historical Data

* Premium members only.

The historical data trend for Renerve's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renerve ROCE % Chart

Renerve Annual Data
Trend Jun22 Jun23 Jun24 Jun25
ROCE %
0.00 0.00 -36.21 -54.98

Renerve Semi-Annual Data
Jun22 Jun23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial 0.00 0.00 -44.13 -61.78 -113.87

Renerve ROCE % Calculation

Renerve's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=-3.484/( ( (7.922 - 0.48) + (6.194 - 0.962) )/ 2 )
=-3.484/( (7.442+5.232)/ 2 )
=-3.484/6.337
=-54.98 %

Renerve's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-6.052/( ( (6.194 - 0.962) + (6.264 - 0.866) )/ 2 )
=-6.052/( ( 5.232 + 5.398 )/ 2 )
=-6.052/5.315
=-113.87 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -113.87% mean?
Renerve (ASX:RNV) has a ROCE % of -113.87% as of Dec. 2025.
Is Renerve's ROCE % too high?
Renerve's current ROCE % is -113.87%.
How does Renerve's ROCE % compare to VRTX and REGN?
Renerve's ROCE % of -113.87% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Renerve's current ROCE % is -113.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renerve stock overvalued right now?
Renerve (ASX:RNV) has a current ROCE % of -113.87%. The current ROCE % is -113.87%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Renerve (ASX:RNV), the current ROCE % is -113.87% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Renerve Business Description

Address 157 Heidelberg Road, Northcote, VIC, AUS, 3070
Renerve Ltd specializes in developing a range of ready-to-use products that are cleaner, safer for repairing or replacing damaged peripheral nerves, resulting in good patient outcomes. Its product candidates include NervAlign Bionic Nerve, NervAlign Nerve Graft, and NervAlign Nerve Cuff [The NervAlign Nerve Guide Matrix, The NervAlign Nerve Conduit, The NervAlign Bionic Replacement Nerve]. The company operates in New Zealand and USA. Maximum of revenue is from USA.